PDSB: PDS Biotechnology Corp Broker Consensus Forecast

The market price action of PDS Biotechnology (PDSB) on the GURU.Markets platform correlates with the use of the Versamune platform to create universal anti-tumor agents, which optimizes expenses. The current indicator stands at 4.48, while PDS Biotechnology (PDSB) relies on external financing due to a lack of profitable products and negative cash flow. Trial safety is guaranteed here by strict temperature control during the transportation of biologics.

PDS Biotechnology Corporation (PDSB): Analyst Consensus Forecast from 07/04/2022 to 11/11/2026

Metric breakdowns and analytics for PDS Biotechnology (PDSB)

- share price and expert price forecast:

Quote Chart pdsbiotech.com|PDSB - Analyst Consensus Forecast

- market capitalization information:

Market Capitalization PDS Biotechnology Corp|PDSB - Total Company Value

- business book valuation details:

Net Assets per Share PDS Biotechnology|PDSB - Book Capitalization|Market Value to Book Value Ratio pdsbiotech.com|PDSB - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

- net income and valuation ratios data:

PDSB - Company Net Income|Expected Net Profit PDS Biotechnology|PDSB - P/E Multiple|Forward Price to Earnings Multiple pdsbiotech.com|PDSB - Price/Earnings to Growth Multiple|Company Value to EBITDA PDS Biotechnology Corp|PDSB - Operating profit before deduction of amortization|Earnings per share for the trailing year PDS Biotechnology|PDSB - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months pdsbiotech.com|PDSB - Earnings per share growth in current year|Expected earnings per share growth for next year PDS Biotechnology

General company analysis:PDSB (PDS Biotech)

This indicator represents the weighted average of target prices from leading analysts over a one-year horizon, allowing investors to filter out short-term noise from real fundamental value. The consensus price target trend for PDS Biotechnology (PDSB) reflects a revision of yield models amid the expansion of the immunotherapeutic vaccine market and growing demand from oncology centers for combination cancer treatment methods.

Competitors of PDS Biotechnology